## Michelle Zalles

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7332495/publications.pdf

Version: 2024-02-01

1307594 1281871 24 137 7 11 citations g-index h-index papers 26 26 26 193 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Molecular changes associated with spinal cord aging. GeroScience, 2020, 42, 765-784.	4.6	25
2	Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model. Journal of Cellular and Molecular Medicine, 2020, 24, 1738-1749.	3.6	21
3	Rapamycin restores brain vasculature, metabolism, and blood-brain barrier in an inflammaging model. GeroScience, 2021, 43, 563-578.	4.6	17
4	Age-related focal loss of contractile vascular smooth muscle cells in retinal arterioles is accelerated by caveolin-1 deficiency. Neurobiology of Aging, 2018, 71, 1-12.	3.1	16
5	Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment. American Journal of Nuclear Medicine and Molecular Imaging, 2019, 9, 93-109.	1.0	12
6	Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model. Translational Oncology, 2020, 13, 100737.	3.7	11
7	Physical confinement during cancer cell migration triggers therapeutic resistance and cancer stem cell-like behavior. Cancer Letters, 2021, 506, 142-151.	7.2	9
8	OKlahoma Nitrone-007: novel treatment for diffuse intrinsic pontine glioma. Journal of Translational Medicine, 2020, 18, 424.	4.4	7
9	Novel approaches to combat chemoresistance against glioblastomas. , 2020, 3, 686-698.		5
10	In vivo and ex vivo assessment of bladder hyper-permeability and using molecular targeted magnetic resonance imaging to detect claudin-2 in a mouse model for interstitial cystitis. PLoS ONE, 2020, 15, e0239282.	2.5	4
11	ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model. Multiple Sclerosis and Related Disorders, 2021, 49, 102786.	2.0	3
12	A tale of two multiâ€focal therapies for glioblastoma: An antibody targeting ELTD1 and nitroneâ€based OKNâ€007. Journal of Cellular and Molecular Medicine, 2022, 26, 570-582.	3.6	3
13	XRN2 Is Required for Cell Motility and Invasion in Glioblastomas. Cells, 2022, 11, 1481.	4.1	2
14	EXTH-07. OPTIMIZATION OF TARGETING ELTD1 IN GLIOBLASTOMA USING A MOLECULAR TARGETING APPROACH. Neuro-Oncology, 2019, 21, vi83-vi83.	1.2	1
15	ELTD1 as a Multi-Focal Target for Malignant Gliomas: Pre-Clinical Studies. Neuro-Oncology Advances, 2021, 3, vdab132.	0.7	1
16	PDTM-04. EARLY DETECTION BY MRI OF MOUSE MODELS WITH DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2019, 21, vi187-vi187.	1.2	0
17	Title is missing!. , 2020, 15, e0239282.		O
18	Title is missing!. , 2020, 15, e0239282.		0

#	Article	IF	CITATIONS
19	Title is missing!. , 2020, 15, e0239282.		О
20	Title is missing!. , 2020, 15, e0239282.		0
21	Title is missing!. , 2020, 15, e0239282.		O
22	Title is missing!. , 2020, 15, e0239282.		0
23	Title is missing!. , 2020, 15, e0239282.		O
24	Title is missing!. , 2020, 15, e0239282.		0